Anti-metastasis therapy: Resistin inhibits epithelial-mesenchymal transition and HEF1 expression via up regulation of its target gene, 10/October/2014, 22.39

Anti-metastasis therapy: Resistin inhibits epithelial-mesenchymal transition and HEF1 expression via up regulation of its target gene, 10/October/2014, 22.39

Anti-metastasis therapy: Resistin inhibits epithelial-mesenchymal transition and HEF1 expression via up regulation of its target gene, 10/October/2014, 22.39 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated byDr L Boominathan Ph.D.

CitationBoominathan, L., Anti-metastasis therapy: Resistin inhibits epithelial-mesenchymal transition and HEF1  expression via up regulation of its target gene, 10/October/2014, 22.38, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Significance: This study suggests that tumor suppressor Resistin, by increasing the expression of its target gene, it may decrease the expression of EMT protein HEF1.  Therefore, pharmacological formulations encompassing “Resistin activators may be used to treat metastatic cancers.